Rendering of AGC Biologics' new facility at Yokohama Technical Center in Japan. (Credit: AGC Biologics)

AGC Bi­o­log­ics to build new gov­ern­ment-fund­ed $350M Japan­ese fa­cil­i­ty

CD­MO AGC Bi­o­log­ics is con­struct­ing a new gov­ern­ment-fund­ed ¥50 bil­lion ($350.5 mil­lion) fa­cil­i­ty at its Yoko­hama Tech­ni­cal Cen­ter in Japan, which is rough­ly half an hour’s dri­ve from West Tokyo.

The new build, an­tic­i­pat­ed to be op­er­a­tional in 2026, will of­fer ser­vices in pre­clin­i­cal and com­mer­cial man­u­fac­tur­ing for mam­malian-based pro­tein bi­o­log­ics, as well as cell ther­a­pies and mR­NA. Ac­cord­ing to the Seat­tle, WA-head­quar­tered man­u­fac­tur­er, this will be one of Japan’s largest mam­malian-based fa­cil­i­ties, hous­ing 2,000L sin­gle-use biore­ac­tors and 4,000L or larg­er re­ac­tors for mam­malian cell cul­ture pro­duc­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.